PRAF2

Across TCGA pan-cancer cohorts, PRAF2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRAF2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRAF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRAF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, LUAD, and CCRCC are the cancer types where PRAF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.312	0.769	.004	23	view →
LUAD	DFS	Tertile	All	0.615	1.000	.005	21	view →
CCRCC	OS	Tertile	II,III,IV	0.614	0.967	.010	17	view →
LSCC	OS	Median	II,III,IV	0.655	0.881	.011	14	view →
PDAC	OS	Tertile	II,III,IV	0.633	0.358	.024	9	view →
HNSC	DFS	Quartile	All	0.315	0.852	.010	6	view →
UCEC	DFS	Median	All	0.850	0.956	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRAF2–GBM (OS)

Open the GBM breakdown →